Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group

American Journal of Hematology

Volumn 64, Issue 3, 2000, Pages 190-196

  Weisenburger, Dennis D ^a,b   Vose, Julie M ^a   Greiner, Timothy C ^a   Lynch, James C ^b   Chan, Wing C ^a   Bierman, Philip J ^a   Dave, Bhavana J ^a   Sanger, Warren G ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anthracycline; Mantle cell lymphoma; Non Hodgkin's lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER GROWTH; CYTOPATHOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL TIME; UNITED STATES;

EID: 0034125783     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B     Document Type: Article

References (54)

1. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-4494.
2. Armitage JO, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998;6:2780-2795.
3. Anderson JR, Armitage JO, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 1998;9:717-720.
4. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
6. Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC, et al. Comparison of front-line chemotherapy for aggressive non-Hodgkin's lymphoma using the CAP-BOP regimens. Sem Hematol 1994(Suppl 3);31:4-8.
7. Brynes RK, McCourty A, Tamayo R, Jenkins K, Battifora H. Demonstration of cyclin Dl (bcl-1) in mantle cell lymphoma. Enhanced staining using heat and ultrasound epitope retrieval. Appl Immunohistochem 1997;5:45-48.
8. Nashelsky MB, Hess MM, Weisenburger DD, Pierson JL, Bast MA, Armilage JO, et al. Cytogenetic abnormalities in B-immunoblastic lymphoma. Lenk Lymph 1994;14:415-420.
9. Dave BJ, Pickering DL, Hess MM, Weisenburger DD, Armitage JO, Sanger WG. Deletion of cell division cycle 2-like 1 gene locus on chromosome lp36 in non-Hodgkin's lymphoma. Cancer Genet Cytogenet 1999;108:120-126.
10. Kaplan E. Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Weisenburger DD, Nathwani BN, Diamond LW, Winberg CD, Rappaport H. Malignant lymphoma, intermediate lymphocytic type. A clinicopathologic study of 42 cases. Cancer 1981;48:1415-1425.
12. Brittinger G, Bartels H, Common H, Duhmke E, Fulle HH, Gunzer U, et al. Clinical and prognostic relevance of the Kiel classification of non-Hodgkin's lymphomas. Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 1984;2:269-306.
13. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257-262.
14. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 1995;13: 2819-2826.
15. Ruskone-Formestraux A, Delmer A, Lavergne A, Molina T. Brousse N, Audouin J, et al. Multiple lymphomatous polyposis of the gastrointestinal tract: a prospective clinicopathologic study of 31 cases. Gastroenterology 1997;112:7-16.
16. Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329-336.
17. Meusers P, Engelhard M, Bartels H, Binder T, Fulle HH, Gorg K, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve prognosis. Hematol Oncol 1989;7:365-380.
18. Norton AJ, Mathews J, Pappa V, Shamash J, Love S, Rohatiner AZ, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995;6:249-256.
19. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-2078.
20. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998;82:567-575.
21. Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12:1281-1287.
22. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including mucosa-associated lymphoid tissue and monocytoid B cell categories): a Southwest Oncology Group study. Blood 1995;85:1075-1082.
23. Stewart DA, Vose JM, Weisenburger DD, Anderson JR, Ruby EI, Bast MA, et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6:263-266.
24. Ketterer N, Salles G, Espinouse D, Dumontet C, Neidhardt-Berard EM, Moullet I, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8:701-704.
25. Blay JY, Sebban C, Surbiquet C, Ouachee M, Philip I, Philip T, et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience in 18 patients. Bone Marrow Transplant 1998;21:51-54.
26. Kroger N, Hoffknecht M, Dreger P, Kruger W, Zeller W, Krull A, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998;21:55-57.
27. Milpied N, Gaillard F, Moreau P, Mahe B, Souchet J, Rapp MJ, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998;22:645-650.
28. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998;16:13-18.
29. Anderson NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997;90:4212-4221.
30. The Non-Hodgkin's Lymphoma Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
31. Weisenburger DD, Sanger WG, Armitage JO, Purtilo DT. Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. Blood 1987;69:1617-1621.
32. Rimokh R, Berger F, Cornillet P, Wahbi K, Rouault JP, French M, et al. Break in the bcl-1 locus is closely associated with intermediate lymphocytic lymphoma subtype. Genes Chromosomes Cancer 1990; 2:223-226.
33. Yang WI, Zukerberg LR, Motokura T, Arnold A, Harris NL. Cyclin D1 (bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994;145:86-96.
34. deBoer CJ, Schuuring E, Dreef E, Peters G, Bartek J, Kluin PM, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995;86:2715-2723.
35. Yatabe Y, Nakamura S, Seto M, Kuroda H, Kagami Y, Suzuki R, et al. Clinicopathologic study of PRAD1/cyclin D1 overexpression with special reference to mantle cell lymphoma. Am J Surg Pathol 1996; 20:1110-1122.
36. Monteil M, Callanan M, Dascalescu C, Sotto JJ, Leroux D. Molecular diagnosis of t(11;14) in mantle cell lymphoma using two-color interphase fluorescence in situ hybridization. Br J Haematol 1996;93:656-660.
37. Vaandrager JW, Schuuring E, Zwikstra E, de Boer CJ, Kleiverda KK, van Krieken JH, et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 1996;88:1177-1182.
38. Siebert R, Matthiesen P, Harder S, Zhang Y, Borowski A, Zuhlke-Jenisch R, et al. Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol 1998; 9:519-526.
39. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3918.
40. Segal GH, Masih AS, Fox AC, Jorgensen T, Scott M, Braylan RC. CD5-expressing B-cell non-Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995;85:1570-1579.
41. Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997;15:1664-1667.
42. Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990;14:752-763.
43. Zoldan MC, Inghirami G, Masuda Y, Vandekerckhove F, Raphael B, Amorosi E, et al. Large cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996;93:475-486.
44. Weisenburger DD, Duggan MJ, Perry DA, Sanger WG, Armitage JO. Non-Hodgkin's lymphomas of mantle-zone origin. In: Rosen PP, Fechner RE, editors. Pathology Annual. East Norwalk, CT: Appleton and Lange; 1990. p 139-158.
45. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803-3809.
46. Corradini P, Ladetto M, Astolfi M, Voena C, Tarella C, Bacigalupo A, et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle cell lymphoma. Br J Haematol 1996;94:376-378.
47. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998;92:1832-1836.
48. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
49. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
50. Zhau P, Jiang W, Zhang Y, Kahn SM, Schieren I, Santella RM, et al. Antisense to cyclin D1 inhibits growth and reverts the transformed phenotype of human esophageal cancer cells. Oncogene 1995;11:571-580.
51. WAFI. Curr Biol 1996;7:71-80.
52. Kim HG, Miller DM. A novel triplex-forming oligonucleotide targeted to human cyclin D1 (bcl-1 proto-oncogene) promoter inhibits transcription in HeLa cells. Biochemistry 1998;37:2666-2672.
53. König A, Schwartz GK, Mohammed RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol down regulates bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307-4312.
54. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998;91:2482-2490.